-+ 0.00%
-+ 0.00%
-+ 0.00%
IceCure Medical nine-month 2026 net loss widens 20% to $13 million
Share
Listen to the news
IceCure Medical nine-month 2026 net loss widens 20% to $13 million
  • IceCure Medical’s net loss widened 20% year over year to $13 million for the nine months ended September 30, 2026.
  • Revenues rose 26% year over year to $2.64 million.
  • Operating cash outflow increased 32% year over year to $12.58 million; cash and cash equivalents totaled $8.22 million at September 30.
  • U.S. commercial reach expanded to 21 states in the third quarter, up from 11 a year earlier.
  • Following quarter-end, the ChoICE breast cancer study enrolled its first two patients and completed its first ProSense cryoablation treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611180825PR_NEWS_USPR_____LN00398) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending